Suppr超能文献

一种用于早期脓毒症识别和治疗的新型生物标志物的预测经济效益:一项反事实分析。

Predicted Economic Benefits of a Novel Biomarker for Earlier Sepsis Identification and Treatment: A Counterfactual Analysis.

作者信息

Paoli Carly J, Reynolds Mark A, Coles Courtney, Gitlin Matthew, Crouser Elliott

机构信息

Health Economics & Reimbursement, Beckman Coulter, Inc., Brea, CA.

Blue Path Solutions, Los Angeles, CA.

出版信息

Crit Care Explor. 2019 Aug 7;1(8):e0029. doi: 10.1097/CCE.0000000000000029. eCollection 2019 Aug.

Abstract

UNLABELLED

To estimate the potential clinical and health economic value of earlier sepsis identification in the emergency department using a novel diagnostic marker, monocyte distribution width.

DESIGN

The analysis was conducted in two phases: 1) an analysis of the pivotal registration trial evidence to estimate the potential benefit of monocyte distribution width for early sepsis identification and (2) a cost-consequence analysis to estimate the potential economic and clinical benefits that could have resulted from earlier administration of antibiotics for those patients.

SETTING

Sepsis identified in the emergency department which led to inpatient hospitalizations.

PATIENTS

Adult sepsis patients admitted through the emergency department.

INTERVENTIONS

None. This was a model simulation of clinical and economic outcomes of monocyte distribution width based on results from a noninterventional, multicenter clinical trial.

MEASUREMENTS AND MAIN RESULTS

Among the 385 patients with sepsis, a total of 349 were eligible for inclusion. Sixty-seven percent of patients were predicted to benefit from monocyte distribution width results, resulting in an estimated mean reduction in time to antibiotics administration from 3.98 hours using standard of care to 2.07 hours using monocyte distribution width + standard of care. Based on this simulated reduction in time to antibiotics, monocyte distribution width + standard of care could have resulted in a less than or equal to 14.2% reduction (27.9% vs 32.5%) in mortality, a mean reduction of 1.48 days (10.0 vs 11.5 d) in length of stay, and $3,460 ($23,466 vs $26,926) savings per hospitalization. At the hospital level, based on an established national mean of 206 sepsis hospitalizations per hospital per year, earlier identification with monocyte distribution width is predicted to result in a total of $712,783 in annual cost savings per hospital.

CONCLUSIONS

Improved early identification of sepsis using monocyte distribution width along with current standard of care is estimated to improve both clinical and economic outcomes of sepsis patients presenting in the emergency department. Further research is warranted to confirm these model projections.

摘要

未标注

使用新型诊断标志物单核细胞分布宽度来评估急诊科早期识别脓毒症的潜在临床和健康经济价值。

设计

分析分两个阶段进行:1)对关键注册试验证据进行分析,以评估单核细胞分布宽度对早期脓毒症识别的潜在益处;(2)进行成本效益分析,以评估对这些患者更早使用抗生素可能带来的潜在经济和临床益处。

背景

在急诊科识别出的脓毒症导致患者住院治疗。

患者

通过急诊科收治的成年脓毒症患者。

干预措施

无。这是基于一项非干预性多中心临床试验结果对单核细胞分布宽度的临床和经济结果进行的模型模拟。

测量指标和主要结果

在385例脓毒症患者中,共有349例符合纳入标准。预计67%的患者将从单核细胞分布宽度结果中获益,这使得预计的抗生素给药时间平均从使用标准治疗的3.98小时减少至使用单核细胞分布宽度+标准治疗的2.07小时。基于这种模拟的抗生素给药时间减少,单核细胞分布宽度+标准治疗可能使死亡率降低至14.2%以下(27.9%对32.5%),住院时间平均减少1.48天(10.0天对11.5天),每次住院节省3460美元(23466美元对26926美元)。在医院层面,基于全国每家医院每年脓毒症住院患者平均206例的既定数据,预计使用单核细胞分布宽度进行早期识别每年可为每家医院节省总计712783美元的成本。

结论

使用单核细胞分布宽度结合当前标准治疗改善脓毒症的早期识别,预计可改善急诊科脓毒症患者的临床和经济结果。有必要进行进一步研究以证实这些模型预测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ba/7063955/ac4ccc02c453/cc9-1-e0029-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验